While age-specific dementia prevalence is falling in many countries, several recent reviews estimate prevalence in Latin America to be higher than anywhere else in the world. This may be, in part, due to the high incidence of socioeconomic and health-related risk factors present in the region. However, growing evidence suggests that primary and secondary prevention via modifiable risk factors is possible, and that 40% of cases may be mitigated through interventions which target modifiable risk. This suggests that there may be significant scope for dementia risk reduction in this region. In June 2021, eight fellows from the Global Brain Health Institute (GBHI) hosted an expert consensus workshop on challenges and opportunities for brain health and dementia prevention in Latin America. The workshop brought together 16 experts in dementia, aging, and brain health from a range of professional backgrounds and geographical regions. From this workshop we collated an expert-led consensus regarding the practical challenges and opportunities implicit in embedding brain health and dementia prevention initiatives in the Latin American context. Here we discuss the outcomes of this workshop, highlighting several challenges and opportunities and discussing how these may be addressed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285633PMC
http://dx.doi.org/10.3389/frdem.2023.1275641DOI Listing

Publication Analysis

Top Keywords

brain health
20
challenges opportunities
16
health dementia
12
dementia prevention
12
latin america
12
prevention latin
8
risk factors
8
modifiable risk
8
dementia
6
health
5

Similar Publications

Article Synopsis
  • A study evaluated the impacts of divalproex sodium on brain volumes in patients with mild to moderate Alzheimer’s disease using MRI scans over 24 months.
  • The results indicated that participants receiving divalproex experienced a significantly higher decline in hippocampal and brain volumes compared to those on placebo, along with a faster decline in cognitive function as measured by the Mini-Mental State Examination.
  • The findings suggest that divalproex treatment is linked to accelerated brain volume loss and potentially increased cognitive impairment, although the long-term effects remain unclear.
View Article and Find Full Text PDF
Article Synopsis
  • The study tested whether divalproex sodium (valproate) could prevent or delay agitation and psychosis in individuals with moderate Alzheimer's disease, enrolling 313 participants.
  • After two years of treatment, results showed no significant difference between the valproate and placebo groups regarding the time to development of agitation or psychosis.
  • Additionally, the valproate group experienced more side effects and showed greater reductions in brain volume, indicating potential adverse effects of the treatment.
View Article and Find Full Text PDF

Objective: To delineate the trajectories of Aβ42 level in cerebrospinal fluid (CSF), fludeoxyglucose F18 (FDG) uptake using positron emission tomography, and hippocampal volume using magnetic resonance imaging and their relative associations with cognitive change at different stages in aging and Alzheimer disease (AD).

Design: Cohort study.

Setting: The 59 study sites for the Alzheimer's Disease Neuroimaging Initiative.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!